Showing results (1-10 of 142) with videos related to
Sort By:
Pageof 15
Therapeutics and Clinical Risk Management|January 2, 2024
Safety and Efficacy of Subcutaneous Daratumumab in Systemic AL AmyloidosisMichael Sang Hughes, Suzanne LentzschExpert Review of Hematology|January 27, 2026
Integrating an updated high-risk multiple myeloma classification into clinical practice and clinical trial epidemiologyMichael Sang Hughes, Suzanne LentzschPresse Medicale (Paris, France : 1983)|December 13, 2024
Primary systemic amyloidosis: A brief overviewMichael Sang Hughes, Suzanne LentzschEuropean Journal of Haematology|February 5, 2025
Treatment of Refractory Monoclonal Immunoglobulin Deposition Disease With BCMA Bispecific AntibodyDivaya Bhutani, Rajshekhar Chakraborty, Karan Wats, et al.European Journal of Haematology|February 24, 2025
Improved Outcomes of Myeloma Cast Nephropathy in Newly Diagnosed Multiple Myeloma With Modern Anti-Myeloma TherapiesMichael Sang Hughes, Metodi Balev, Jai Radhakrishnan, et al.Bone Marrow Transplantation|December 27, 2025
CAR T-cells in multiple myeloma: the race to the start lineAbdul-Hamid Bazarbachi, Divaya Bhutani, Michael Sang Hughes, et al.Seminars in Oncology|January 8, 2017
High-risk smoldering myeloma: Perspective on watchful monitoringSiyang Leng, Suzanne LentzschCurrent Hematologic Malignancy Reports|October 26, 2013
Multiple myeloma: Defining the high-risk patient and determining the optimal treatment strategyJordan Schecter, Suzanne LentzschDrug News & Perspectives|November 10, 2007
Treatment of multiple myeloma with SDX-308Rentian Feng, Suzanne LentzschPharmacology & Therapeutics|July 17, 2012
The application and biology of immunomodulatory drugs (IMiDs) in cancerBeiqing Pan, Suzanne LentzschPageof 15